price apr usd
revenu usdm
hold rate reflect skeptic compani abl
attain sale growth margin target result sale growth
oper margin expans outpac estim detract thesi
thing like
 sale growth ep beat organ sale growth came
ahead consensus-lik estim diagnost busi
drove out-performance moreov exclud advers time
impact govern shutdown organ sale growth would
adjust ep came consensus-lik
estim beat driven primarili better margin
ep guid rais reflect cisbio acquisit rais
adjust ep guidanc rang
reflect accret cysbio acquisit conjunct
result releas announc acquisit cisbio bioassay
manufactur custom kit reagent broaden capabl
research drug discoveri market
 biopharma growth robust report high-single-digit growth
biopharma end market mar-qtr manag note mar-qtr
fourth consecut quarter double-digit growth imag
grew high-single-digit pace exclud advers impact
govern shutdown manag note strength across end
market includ biopharma diagnost partial off-set
soft appli market still expect high-single-digit growth
china
thing cautiou
 growth guid margin expans remain load order achiev
organ sale growth guid target acceler
organ sale growth despit tough comp back
half year manag confid growth ramp reflect
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
revers timing-rel issu well new product momentum
oper margin expans basi point bp also
weight toward back half year
 europ declin low-singl digit mar-qtr europ declin low-
single-digit pace pressur come appli academ end
market diagnost continu perform well europ manag
growth expect europ remain unchang low-singl
pt
rais pt reflect roll forward valuat
framework higher tool peer group multipl price target reflect
enterpris valu use project level debt cash ebitda
ex option estim end multipl equiva-
lent life scienc tool diagnost peer group median
period end expens expens incom incom continu ep dilut con share share sale ex amort acquir cash flowoper cash cash revenu ep incl
period end asset equival st receiv current discontinu current equip secur asset asset asset discontinu liabil short-term liabil discontinu op current debt less current long-term liabil stockhold april
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur primari
subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/research/disclosures/
companysearch asid within report import risk conflict disclosur also found investor
strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
deutsch bank and/or affili receiv non-invest bank relat compens compani
within past year
compani client deutsch bank secur inc within past year time receiv
import disclosur requir non-u regul
